Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma
Scott P. Campbell(Johns Hopkins University), Michael A. Gorin(Johns Hopkins University), Mark W. Ball(Johns Hopkins University), Martin G. Pomper(Southwestern Medical Center), Michael H. Johnson(Johns Hopkins University), Alexander S. Baras(Johns Hopkins University), Steven P. Rowe(Johns Hopkins Medicine), Trinity J. Bivalacqua(University of Pennsylvania), Noah M. Hahn(Johns Hopkins University), Max Kates(Duke Medical Center), Mohamad E. Allaf(Johns Hopkins University)
Cited by 34
Related Papers
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k